A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2018 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
- 10 Jun 2017 Biomarkers information updated
- 15 Feb 2017 Planned primary completion date changed from 1 Jun 2020 to 1 Mar 2020.